Clinical trial · Interventional
Prospective Study to Compare the Efficacy of E.G.Scan to Detect Barrett's Esophagus Compared With Standard Endoscopy
NCT02066233CI-TRIAL-00028498completedN/AResults postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study was to evaluate whether a disposable nasal endoscope called "E.G. Scan II" will visualize the esophagus as well as the standard test, sedated endoscopy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Barrett's Esophagus | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| EG Scan II (transnasal endoscopy) | Device | — | UNRESOLVED |
| Standard Endoscopy | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- Subjects with Barrett's Esophagus
- description
- All subjects will receive transnasal endoscopy (EG Scan II) followed by standard endoscopy.
- interventionNames
- Device: EG Scan II (transnasal endoscopy)
- Procedure: Standard Endoscopy
- type
- ACTIVE_COMPARATOR
- label
- Subjects with Reflux and/or Heartburn
- description
- All subjects will receive EG Scan II (transnasal endoscopy) followed by standard endoscopy.
- interventionNames
- Device: EG Scan II (transnasal endoscopy)
- Procedure: Standard Endoscopy
Primary outcomes (1)
- measure
- Median Tolerability Score on 10-point Visual Analog Scale (VAS)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Adult participants aged 18 years or above who are scheduled for routine upper GI endoscopy for Barrett's Esophagus surveillance, varices surveillance and dyspepsia. 2. Able and willing to give informed consent. Exclusion Criteria: 1. Patients known to be intolerant to endoscopy. 2. Patients with frequent epistaxis. 3. Patients not clinically fit for endoscopy as judged by their care team. 4. Pregnant women. 5. Patients with allergy/sensitivity to Simethicone (Mylicon), Phenylephrine, Lidocaine nasal spray, Benzocaine spray (Topex) 6. Use of anticoagulants or antiplatelets.
References
Publications (1)
- DERIVEDSami SS, Iyer PG, Pophali P, Halland M, di Pietro M, Ortiz-Fernandez-Sordo J, White JR, Johnson M, Guha IN, Fitzgerald RC, Ragunath K. Acceptability, Accuracy, and Safety of Disposable Transnasal Capsule Endoscopy for Barrett's Esophagus Screening. Clin Gastroenterol Hepatol. 2019 Mar;17(4):638-646.e1. doi: 10.1016/j.cgh.2018.07.019. Epub 2018 Aug 3. PMID 30081223